12:00 AM
 | 
Jun 16, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pollinex Quattro Grass: Additional Phase III data

Allergy Therapeutics reported additional data from the double-blind, U.S., Canadian and European Phase III G301 trial in 1,028 patients. In patients with severe seasonal allergic rhino-conjunctivitis caused by grass pollen, Pollinex Quattro Grass vaccine reduced the combined symptom/medication score by 17% vs. placebo (p=0.0023). Patients receiving...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >